ERJerjEuropean Respiratory JournalEur Respir J0903-19361399-3003European Respiratory Society10.1183/13993003.02058-2019ERJ-02058-2019AGORARESEARCH LETTER

Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosisB. CLYNICK ET AL.RESEARCH LETTERCirculating RNA differences between patients with stable and progressive IPF

ClynickBritt[1,2],JoHelenE.[3,4], CorteTameraJ.[3,4], GlaspoleIanN.[5,6], GraingeChristopher[7,8],HopkinsPeterM.A.[9,10], ReynoldsPaulN.[11,12], ChapmanSally[12],WaltersE. Haydn[6,13,14,15], ZappalaChristopher[9],KeirGregoryJ.[9], CooperWendyA.[3,4,16], MaharAnnabelleM.[3,4], EllisSamantha[6],GohNicoleS.[17,18], BalticSvetlana[1,2],RyanMarisa[1,2],TanDinoB.A.[1,2], MoodleyYubenP.[1,2,19],

1Institute for Respiratory Health, Nedlands, Australia. 2University of Western Australia, Crawley, Australia. 3University of Sydney, Camperdown, Australia. 4Royal Prince Alfred Hospital, Camperdown, Australia. 5Monash University, Clayton, Australia. 6Alfred Hospital, Melbourne, Australia. 7University of Newcastle, Callaghan, Australia. 8John Hunter Hospital, New Lambton Heights, Australia. 9University of Queensland, St Lucia, Australia. 10Prince Charles Hospital, Chermside, Australia. 11University of Adelaide, Adelaide, Australia. 12Royal Adelaide Hospital, Adelaide, Australia. 13University of Tasmania, Hobart, Australia. 14University of Melbourne, Parkville, Australia. 15Royal Hobart Hospital, Hobart, Australia. 16Western Sydney University, Sydney, Australia. 17Austin Hospital, Heidelberg, Australia. 18Institute of Breathing and Sleep, Heidelberg, Australia. 19Fiona Stanley Hospital, Murdoch, Australia.

Correspondence: Yuben P. Moodley, School of Medicine, University of Western Australia, Level 2, Harry Perkins Institute of Medical Research, Fiona Stanley Hospital Campus, 5 Robin Warren Drive, Murdoch WA 6150, Australia. E-mail: yuben.moodley@uwa.edu.au20202020560221020198042020202020

To the Editor:

Idiopathic pulmonary fibrosis (IPF) is a chronic disease characterised by progressive decline in pulmonary function. The rate of decline can vary, with some patients remaining stable over longer periods of time and others rapidly progressing [1]. The variable progression of this disease makes it difficult to elucidate pathogenic pathways involved in the initiation and progression of IPF. Advances in high-throughput gene-expression analyses have led to improvements in our understanding of disease biology and prognostic gene signatures. We hypothesise that IPF has a unique circulatory transcriptional profile compared to healthy controls, with additional differences between stable and progressive disease likely related to disease pathogenesis.